A new aminopeptidase inhibitor from Streptomyces strain HCCB10043 found by UPLC-MS |
| |
Authors: | Rao Min Li Qiushuang Feng Lei Xia Xing Ruan Lijun Sheng Xiafang Ge Mei |
| |
Institution: | (1) College of Life Science, Nanjing Agricultural University, Nanjing, 210095, Jiangsu, China;(2) Shanghai Laiyi Center for Biopharmaceuticals R&D, Shanghai, 201203, China;(3) School of Pharmacy, Shanghai Jiao Tong University, 800 Dong Chuan Road, Minhang, Shanghai, 200240, China;(4) Instrumental Analysis Center, Shanghai Jiao Tong University, Shanghai, 200240, China |
| |
Abstract: | The diversity of microbial metabolites has been of interest and concern for a long time, yet a suitable method for discovering
these is still unavailable. In the work discussed in this report, ultra-performance liquid chromatography coupled with tandem
quadrupole and time of flight high-resolution mass spectrometry (UPLC–Q–TOF-HRMS), with MS data analysis, was set up to study
the metabolites of Streptomyces strain HCCB10043. It was found that besides antibacterial substances (A21978C complex) and two anti-aminopeptidase compounds
(valistatin and bestatin), this strain can produce a new aminopeptidase inhibitor, identified as 3-amino-2-hydroxy-4-phenylbutanoylvalylisoleucine.
This new compound had greater activity than valistatin or bestatin in aminopeptidase N (APN) inhibition assay. The results
proved that combination of UPLC–Q–TOF-MS analysis and classic purification and identification steps as complementary strategies
can provide a method with high reliability for research on microbial secondary metabolites. Furthermore, it has shown that
the study of secondary metabolic profiling might be the key to discovering new drugs. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|